deliprom
us pharmacia sp. z o.o. - ibuprofenas - minkštosios kapsulės - 200 mg - ibuprofen
balance 2,3% gliukozės, 1,75 mmol/l kalcio
fresenius medical care deutschland gmbh - natrio chloridas/natrio laktatas/kalcio chlorido dihidratas/magnio chloridas heksahidratas/gliukozė - pilvaplėvės ertmės dializės tirpalas - 5,64 g/3,925 g/0,1838 g/0,1017 g/42,5 g/1000 ml; 5,64 g/3,925 g/0,1838 g/0,1017 g/22,73 g/1000 ml; 5,64 g/3,925 g/0,1838 g/0,1017 g/15 g/1000 ml; 5,64 g/3,925 g/0,2573 g/0,1017 g/22,73 g/1000 ml; 0,2573 g/5,64 g/3,925 g/0,1017 g/42,5 g/1000 ml; 5,64 g/3,925 g/0,2573 g/0,101 - hypertonic solutions
vaprox biocidal product family (vaprox® hydrogen peroxide sterilant, vaprox® 59 hydrogen peroxide sterilant).
steris ireland limited, ida business and technology park, country offialy, tullamore, r35 x865 (airija). - vandenilio peroksidas - veikliosios medžiagos cas nr.: 7722-84-1, eb nr.: 231-765-0, veikliosios medžiagos pavadinimas: vandenilio peroksidas, koncentracija: 59.4% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui
vesta-syde™ sq
steris ireland limited, ida business and technology park, tullamore, county offaly, r35 x865 (airija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 10.5% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui
vesta-syde™ sq st
steris ireland limited, ida business and technology park, tullamore, county offaly, r35 x865 (airija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 10.5% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui
szczepionka przeciwgruźlicza bcg 10
biomed-lublin wytwórnia surowic i szczepionek s.a. - bcg bakterijos (bacillus calmette-guerin), brazilian moreau sub-padermė - milteliai ir tirpiklis injekcinei suspensijai - 50 µg - tuberculosis, live attenuated
alymsys
mabxience research sl - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.
fludeoxyglucose (18f) life radiopharma
life radiopharma berlin gmbh - fludeoksigliukozė (18f) - injekcinis tirpalas - 300-3100 mbq/ml - fludeoxyglucose (18f)
natrio fluoridas (18f) life radiopharma
life radiopharma berlin gmbh - natrio fluoridas (18f) - injekcinis tirpalas - 0,1-4 gbq/ml - sodium fluoride (18f)
druniler
sandoz d.d. - febuksostatas - plėvele dengtos tabletės - 80 mg; 120 mg - febuxostat